



QUE Oncology launches Phase II trials

Biotech creating a new therapy for hot flushes in breast cancer patients launches clinical trials across Australia

Melbourne, AUSTRALIA, 2 October 2018 – Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flushes and night sweats, tested at six sites across Australia.

QUE Oncology is developing drugs for large unmet medical needs and has already advanced clinical development of its lead drug program Q-122, through four Phase 1 trials.

Que Oncology is now set to move Q-122 into a pivotal proof-of-concept trial to examine the efficacy of the drug at leading clinical sites across Melbourne, Sydney Perth and Adelaide. The placebo-controlled, double-blind study will see a total of 130 women take part, with the trial expected to take up to eight months to complete. Leading hospitals in the USA will also participate in the study.

After a diagnosis of breast cancer, women are routinely prescribed drugs such as tamoxifen or aromatase inhibitors (known as endocrine therapy) which reduce or block the action of estrogen, a hormone known to stimulate the growth of breast cancer. However, the side effect of reducing estrogen is an increased likelihood of moderate to severe hot flushes and night sweats. These symptoms can severely impact a women's general wellbeing and often cause women to stop taking their breast cancer treatment. QUE Oncology is looking to develop a therapy to address these debilitating symptoms.

Previous trials with Q-122 have shown an excellent safety profile in over 60 patients and healthy volunteers. In a previous Phase 1b trial in women undergoing estrogen reduction therapy for breast cancer, 85% of women showed a reduction in both the frequency and severity of their hot flushes.

QUE Oncology Chief Executive Officer Dr Rob Crombie says, "Evidence shows that up to 75% of women undergoing long-term preventative breast cancer treatment suffer hot flushes and night sweats, with some facing more than 20 events in one day. We expect through our Phase II trials to replicate the data that we have already seen in this patient group as we develop a treatment to substantially improve the quality of life for women on long-term endocrine therapy."

Specialist endocrinologist Professor Susan Davis, President of the International Menopause Society and Chair of Women's Health at Monash University, will head the trials as lead clinical investigator.

Prof Davis says, "Many people don't understand the full impact of hot flushes and night sweats. They can be debilitating and negatively affect overall quality of life. There is a desperate need for clinical trials of treatments for hot flushes experienced by women undergoing breast cancer therapy."

QUE Oncology's products also have the potential to expand into related conditions, such as hot flushes associated with menopause, and hot flushes experienced by men undergoing prostate cancer treatment.



Women interested in participating in QUE Oncology's clinical trials should visit www.queoncology.com

ENDS

Notes to Editors:

For further information or to arrange an interview, please contact:

QUE Oncology: Andrew Hamilton, ah@manacommunications.com, +61 420 447 669

About QUE Oncology, Inc.

QUE Oncology, Inc. is a clinical stage biotechnology company developing drugs for large unmet medical needs. The company's lead drug program, Q-122 is focused on the treatment of hot flashes in breast cancer survivors undergoing hormone therapy. Several clinical studies with Q-122 have shown the drug to be safely administered to over 60 patients and healthy volunteers.

QUE Oncology was jointly established by Emory University (Atlanta, GA) and the University of Queensland's main commercialisation company, UniQuest Pty Ltd. The Series A investment round was led by the Medical Research Commercialisation Fund (MRCF), with participation by Uniseed, UniQuest, Emory University and Centrosome Ventures.

Que Oncology is now commencing a placebo-controlled Phase 2 study in breast cancer patients, with 130 patients in 10 sites across Australia and the USA. Backed by a recent A\$21.5M capital raise (June 2017) led by Australia's Medical Research Commercialisation Fund (MRCF) and Uniseed, QUE is well funded to execute on its clinical development programs.